We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+7.51%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.46B
AUM Growth
-$38.8M
Cap. Flow
-$22M
Cap. Flow %
-1.5%
Top 10 Hldgs %
61.18%
Holding
86
New
16
Increased
26
Reduced
28
Closed
12

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$44.8M
2
RGEN icon
Repligen
RGEN
+$29.2M
3
INSP icon
Inspire Medical Systems
INSP
+$21.3M
4
NVO
Novo Nordisk
NVO
+$11.2M
5
HCA icon
HCA Healthcare
HCA
+$10.3M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$61.4M
2
PFE icon
Pfizer
PFE
+$30.6M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$26.2M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$20.1M
5
THC icon
Tenet Healthcare
THC
+$18.5M

Sector Composition

Rank Sector Weight
1 Healthcare 88.85%
2 Miscellaneous 11.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNKD icon
26
MannKind Corp
MNKD
$1.27B
$11.8M 0.81%
2,256,952
-134,176
-6% -$609K
BKD icon
27
Brookdale Senior Living
BKD
$2.8B
$10.6M 0.72%
1,546,842
+228,077
+17% +$1.54M
DHR icon
28
Danaher
DHR
$152B
$10.2M 0.7%
40,855
– –
XBI icon
29
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$9.27M 0.63%
+100,000
New +$8.97M
TVTX icon
30
Travere Therapeutics
TVTX
$6.19B
$8.97M 0.61%
1,091,165
+135,547
+14% +$913K
ELV icon
31
Elevance Health
ELV
$85.5B
$7.94M 0.54%
14,657
+264
+2% +$140K
ARQT icon
32
Arcutis Biotherapeutics
ARQT
$2.99B
$7.79M 0.53%
+837,847
New +$7.58M
CNC icon
33
Centene
CNC
$32B
$7.68M 0.53%
115,820
+23,034
+25% +$1.68M
VRDN icon
34
Viridian Therapeutics
VRDN
$2.61B
$7.38M 0.51%
567,487
+425,412
+299% +$5.89M
VKTX icon
35
Viking Therapeutics
VKTX
$3.75B
$7.34M 0.5%
138,489
+115,671
+507% +$7.58M
PCVX icon
36
Vaxcyte
PCVX
$8.9B
$7.26M 0.5%
96,089
-101,242
-51% -$6.89M
BCRX icon
37
BioCryst Pharmaceuticals
BCRX
$2.51B
$7.12M 0.49%
1,152,573
-279,854
-20% -$1.54M
CYTK icon
38
Cytokinetics
CYTK
$10B
$6.87M 0.47%
+126,877
New +$7.66M
NAMS icon
39
NewAmsterdam Pharma
NAMS
$3.1B
$6.34M 0.43%
329,890
-24,075
-7% -$483K
EOLS icon
40
Evolus
EOLS
$587M
$6.23M 0.43%
+574,462
New +$7.07M
MOH icon
41
Molina Healthcare
MOH
$10.4B
$5.43M 0.37%
18,277
+12,449
+214% +$4.23M
STRO icon
42
Sutro Biopharma
STRO
$339M
$5.1M 0.35%
173,913
+64,771
+59% +$2.56M
GOSS icon
43
Gossamer Bio
GOSS
$83.2M
$4.94M 0.34%
5,484,148
-510,324
-9% -$382K
OSCR icon
44
Oscar Health
OSCR
$9.4B
$4.92M 0.34%
+310,893
New +$5.71M
CERE
45
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$4.5M 0.31%
+110,010
New +$4.58M
LQDA icon
46
Liquidia Corp
LQDA
$6.06B
$4.48M 0.31%
373,554
-22,633
-6% -$300K
MYGN icon
47
Myriad Genetics
MYGN
$302M
$4.45M 0.3%
+181,961
New +$3.99M
PBYI icon
48
Puma Biotechnology
PBYI
$468M
$4.33M 0.3%
1,328,454
-98,043
-7% -$430K
KPTI icon
49
Karyopharm Therapeutics
KPTI
$42.4M
$4.33M 0.3%
332,479
-1,942
-0.6% -$32.2K
TSVT
50
DELISTED
2seventy bio
TSVT
$4.26M 0.29%
1,107,743
-69,935
-6% -$315K
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2024 Portfolio in Review

As of Q2 2024, Eversept Partners held 86 positions worth $1.46B, down 2.6% from $1.5B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Eversept Partners's Q2 2024 filing shows 16 new, 26 increased, 28 reduced and 12 closed positions. Its largest new stake was Insmed: 1,155,588 shares worth $77.4M. The largest sale was Natera, an estimated $61.4M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 89% a quarter earlier, followed by Miscellaneous.

  • Eversept Partners's largest Q2 2024 buy was Insmed: 1,155,588 shares worth $77.4M.
  • Eversept Partners added most to Repligen in Q2 2024, an estimated $29.2M increase.
  • Eversept Partners's biggest Q2 2024 reduction was Natera, cutting an estimated $61.4M.
  • Eversept Partners fully exited Pfizer in Q2 2024, selling an estimated $30.6M.
  • Eversept Partners's ten largest holdings make up 61% of its $1.46B portfolio in Q2 2024.
  • Eversept Partners opened 16 new positions and closed 12 in Q2 2024.
  • Eversept Partners's portfolio value fell 2.6% quarter-over-quarter to $1.46B.

Based on Eversept Partners's 13F filing for Q2 2024, filed 14 Aug 2024.